Position in SVRA
as of Jun 30, 2026
· filed Aug 5, 2026
Position Value
$19,394,384
+$987,168 QoQ
Shares Held
3,148,439
-6.6% QoQ
Ownership
1.53%
of shares outstanding
% of Portfolio
0.46%
of 13F equity value
Holder Rank
#19
of 181 holders
Holding Since
Dec 2024
7 quarters on record
Voting authority
Sole 73%
Shared 0%
None 27%
Common Shares in SVRA Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026EMERALD ADVISERS, LLC holds $600,984,884 across 23 Biotechnology names. SVRA ranks #13 (3.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | TVTX |
Travere Therapeutics, Inc.
|
1,600,886 | $90,946,333 | |
| 2 | CORT |
Corcept Therapeutics Inc
|
748,325 | $65,066,858 | |
| 3 | COGT |
Cogent Biosciences, Inc.
|
1,603,319 | $62,048,445 | |
| 4 | MIRM |
Mirum Pharmaceuticals, Inc.
|
468,295 | $54,823,295 | |
| 5 | SYRE |
Spyre Therapeutics, Inc.
|
567,430 | $50,376,435 | |
| 6 | CYTK |
Cytokinetics Inc
|
457,956 | $39,013,271 | |
| 7 | MANE |
Veradermics, Inc
|
288,370 | $35,452,207 | |
| 8 | PVLA |
Palvella Therapeutics, Inc.
|
229,486 | $35,070,050 |
All Filings in SVRA
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $19,394,384 | 3,148,439 | Shares | Sole | 2026-08-05 | |
| 2026-03-31 | $18,407,216 | 3,371,285 | Shares | Sole | 2026-05-04 | |
| 2025-12-31 | $21,077,840 | 3,495,496 | Shares | Sole | 2026-02-09 | |
| 2025-09-30 | $12,599,686 | 3,529,324 | Shares | Sole | 2025-10-30 | |
| 2025-06-30 | $8,058,359 | 3,534,368 | Shares | Sole | 2025-08-04 | |
| 2025-03-31 | $8,559,890 | 3,090,213 | Shares | Sole | 2025-05-01 | |
| 2024-12-31 | $7,161,327 | 2,332,680 | Shares | Sole | 2025-02-11 | |
| No filing history on record for this holder in this stock. | ||||||